Atlas Trials

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Clinical trial NCT06998524 · RECRUITING

Trial details

NCT number
NCT06998524
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Von Willebrand Disease, Type 3
Start date
2025-06-27
Primary completion
2027-04-30
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.